CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 272,704 shares of the company’s stock after purchasing an additional 22,414 shares during the quarter. Pictet Asset Management Holding SA owned about 0.32% of CRISPR Therapeutics worth $10,734,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in CRSP. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after buying an additional 1,474,439 shares during the last quarter. State Street Corp grew its holdings in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares in the last quarter. FMR LLC raised its stake in CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after acquiring an additional 23,075 shares in the last quarter. Vanguard Group Inc. boosted its position in CRISPR Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after acquiring an additional 10,579 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares during the period. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on CRSP. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. The Goldman Sachs Group dropped their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $34.19 on Thursday. The firm has a market cap of $2.93 billion, a PE ratio of -7.82 and a beta of 1.85. CRISPR Therapeutics AG has a twelve month low of $32.51 and a twelve month high of $67.88. The firm’s 50 day moving average price is $42.60 and its 200 day moving average price is $44.90.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last 90 days. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.